Oxidized low density lipoprotein increases RANKL level in human vascular cells. Involvement of oxidative stress

Biochemical and Biophysical Research Communications

Volumn 440, Issue 2, 2013, Pages 295-299

  Mazière, Cécile ^a   Salle, Valéry ^b,c   Gomila, Cathy ^a   Mazière, Jean Claude ^a  

^a University Hospitals   (France)

^b Northern Hospital   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Myocardial inflammation; Oxidative stress; Oxidized LDL; RANKL; Vascular calcification

Indexed keywords

BUTHIONINE SULFOXIMINE; CUPROUS ION; MYELOPEROXIDASE; OSTEOCLAST DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL RUPTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; MYOCARDITIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRAVIOLET A RADIATION;

BSO; BUTHIONINE SULFOXIMINE; CU(2+)-OXIDIZED LDL; CULDL; H(2)O(2); HCASMC; HUMAN CORONARY ARTERY SMOOTH MUSCLE CELLS; HYDROGEN PEROXIDE; LDL; LOW DENSITY LIPOPROTEIN; MPO-LDL; MYELOPEROXIDASE-OXIDIZED LDL; MYOCARDIAL INFLAMMATION; NFAT; NUCLEAR FACTOR OF ACTIVATED T CELLS; OPG; OSTEOPROTEGERIN; OXIDATIVE STRESS; OXIDIZED LDL; OXLDL; RANKL; REACTIVE OXYGEN SPECIES; RECEPTOR ACTIVATOR OF NFKAPPAB LIGAND; ROS; VASCULAR CALCIFICATION;

HUMANS; LIPOPROTEINS, LDL; MUSCLE, SMOOTH, VASCULAR; NFATC TRANSCRIPTION FACTORS; OLIGOPEPTIDES; OSTEOPROTEGERIN; OXIDATIVE STRESS; PEROXIDASE; RANK LIGAND;

EID: 84885847207     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.072     Document Type: Article

References (25)

1. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
2. Silva I., Branco J.C. Rank/Rankl/opg: literature review. Acta. Reumatol. Port. 2011, 36:209-218.
3. Sattler A.M., Schoppet M., Schaefer J.R., Hofbauer L.C. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif. Tissue. Int. 2004, 74:103-106.
4. Tintut Y., Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J. Investig. Med. 2006, 54:395-401.
5. Leibbrandt A., Penninger J.M. RANK/RANKL: regulators of immune responses and bone physiology. Ann. N Y Acad. Sci. 2008, 1143:123-150.
6. Breuil V., Schmid-Antomarchi H., Schmid-Alliana A., Rezzonico R., Euller-Ziegler L., Rossi B. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. Faseb. J. 2003, 17:1751-1753.
7. Seshasayee D., Wang H., Lee W.P., Gribling P., Ross J., Van Bruggen N., Carano R., Grewal I.S. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J. Biol. Chem. 2004, 279:30202-30209.
8. Kvietys P.R., Granger D.N. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free. Radic. Biol. Med. 2012, 52:556-592.
9. Mazière C., Mazière J.C. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free. Radic. Biol. Med. 2009, 46:127-137.
10. Mazière C., Gomila C., Mazière J.C. Oxidized low-density lipoprotein increases osteopontin expression by generation of oxidative stress. Free. Radic. Biol. Med. 2010, 48:1382-1387.
11. Mazière C., Morlière P., Massy Z., Kamel S., Louandre C., Conte M.A., Mazière J.C. Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. Free. Radic. Biol. Med. 2005, 38:472-480.
12. McCaffrey P.G., Goldfeld A.E., Rao A. The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J. Biol. Chem. 1994, 269:30445-30450.
13. Havel R.J., Eden H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 1955, 34:1345-1353.
14. Podrez E.A., Schmitt D., Hoff H.F., Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 1999, 103:1547-1560.
15. Yagi K. Lipid peroxide and human diseases. Chem. Phys. Lipids. 1987, 45:337-351.
16. Graham L.S., Parhami F., Tintut Y., Kitchen C.M., Demer L.L., Effros R.B. Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin. Immunol. 2009, 133:265-275.
17. Jain J., McCaffrey P.G., Miner Z., Kerppola T.K., Lambert J.N., Verdine G.L., Curran T., Rao A. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993, 365:352-355.
18. Tseng W., Graham L.S., Geng Y., Reddy A., Lu J., Effros R.B., Demer L., Tintut Y. PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J. Biol. Chem. 2010, 285:29925-29931.
19. Bai X.C., Lu D., Liu A.L., Zhang Z.M., Li X.M., Zou Z.P., Zeng W.S., Cheng B.L., Luo S.Q. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J. Biol. Chem. 2005, 280:17497-17506.
20. Mazière C., Salle V., Gomila C., Mazière J.C. Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NFkappaB and NFAT. Biochim. Biophys. Acta. 2013, 1832:1756-1764.
21. Holvoet P., Jenny N.S., Schreiner P.J., Tracy R.P., Jacobs D.R. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2007, 194:245-252.
22. Awan Z., Alrasadi K., Francis G.A., Hegele R.A., McPherson R., Frohlich J., Valenti D., de Varennes B., Marcil M., Gagne C., Genest J., Couture P. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2008, 28:777-785.
23. Goettsch C., Rauner M., Hamann C., Sinningen K., Hempel U., Bornstein S.R., Hofbauer L.C. Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. Diabetologia 2011, 54:2690-2701.
24. Sandberg W.J., Yndestad A., Øie E., Smith C., Ueland T., Ovchinnikova O., Robertson A.K., Müller F., Semb A.G., Scholz H., Andreassen A.K., Gullestad L., Damås J.K., Frøland S.S., Hansson G.K., Halvorsen B., Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler. Thromb. Vasc. Biol. 2006, 26:857-863.
25. Kiechl S., Schett G., Schwaiger J., Seppi K., Eder P., Egger G., Santer P., Mayr A., Xu Q., Willeit J. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007, 116:385-391.